Because initiation or switching of antihyperglycemics occur rather infrequently around the time of SARS-CoV-2, this precluded us from developing an incident user design where exposure would be defined as incident use of SGLT2 inhibitors or other antihyperglycemics at the time of infection; instead, we evaluated the effect of current use of SGLT2 inhibitors within those who initiated this treatment within one year of SARS-CoV-2 infection. This evidence concerns the gene SLC5A2 and infection.